跳转至内容
Merck
CN

主要文件

查看所有文档

Y0001133

Docetaxel trihydrate

European Pharmacopoeia (EP) Reference Standard

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C43H53NO14 · 3H2O
化学文摘社编号:
148408-66-6
分子量:
861.93
UNSPSC Code:
41116107
NACRES:
NA.24
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

grade

pharmaceutical primary standard

API family

docetaxel

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

N([C@H]([C@@H](O)C(=O)O[C@H]2C[C@]3([C@H]([C@@H]5[C@]6([C@H](OC6)C[C@@H]([C@]5(C(=O)[C@@H](C(=C2C)C3(C)C)O)C)O)OC(=O)C)OC(=O)c4ccccc4)O)c1ccccc1)C(=O)OC(C)(C)C.O.O.O

InChI

1S/C43H53NO14.3H2O/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45;;;/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52);3*1H2/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+;;;/m0.../s1

InChI key

XCDIRYDKECHIPE-QHEQPUDQSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Docetaxel trihydrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Eye Irrit. 2 - Repr. 1B

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

监管及禁止进口产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Sherry X Yang et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 14(18), 5893-5899 (2008-09-17)
To identify biomarkers and gene expression profile signatures to distinguish patients with partial response (PR) from those with stable disease (SD) and progressive disease (PD). Twenty patients with inflammatory breast cancer and one patient with locally advanced breast cancer received
Giuseppe Di Lorenzo et al.
European urology, 54(5), 1089-1094 (2008-02-16)
Although the taxanes represent the most active agents for the first-line treatment of metastatic hormone-refractory prostate cancer (HRPC), most patients eventually progress while receiving taxane-based treatments. No agents are approved for second-line therapy in HRPC, but common standard practice for
William N William et al.
Cancer, 116(10), 2401-2408 (2010-03-13)
Bevacizumab has recently been demonstrated to prolong overall survival when added to carboplatin and paclitaxel for chemotherapy-naïve patients with nonsquamous nonsmall-cell lung cancer (NSCLC). However, the effects of combining bevacizumab with other standard, front-line, platinum-based doublets have not been extensively
查看所有相关文献

全球贸易项目编号

货号GTIN
Y000113304061833797150